Lei Lei Wu

When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints News.

As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given around surgery, researchers reported Sunday.

All 18 multiple myeloma patients who have received Kelonia’s in vivo CAR-T therapy thus far have responded to treatment, according to an update shared Sunday.

ASCO: Incyte details Monjuvi’s frontline data in lymphoma; Lilly appears in two plenaries

Legend Biotech's long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field.

Elicio's KRAS cancer vaccine failed to cut recurrence or death vs. observation in a 144-patient Phase 2 trial, plunging shares 70%; company seeks funding for a Phase 3 restricted to R0 patients.

Be Biopharma disclosed in a federal clinical trials listing that it has terminated its study of a hemophilia B therapy made by editing a patient’s own cells. It was one of just a few trials examining a B cell therapy.

Triveni Bio closes a $65M Series C to fund two eczema drug candidates targeting kallikreins and IL-13, with Phase 2a data on lead asset TRIV-509 expected by year-end.

Novocure's Optune Gio fails Phase 3 TRIDENT trial in newly diagnosed glioblastoma; overall survival nearly identical in early-use vs. approved arm. Shares drop 17%.

Regenxbio plans to resubmit its Hunter syndrome gene therapy RGX-121 after the FDA reversed course, saying existing data are sufficient for accelerated approval review.